15 results about "Streptococcal strain" patented technology

The invention discloses a primer probe combination for identifying a group A streptococcus M1UK strain and application of the primer probe combination, and belongs to the technical field of streptococcus mutant strain detection. The primer probe combination provided by the invention can specifically amplify the target gene of the M1UK strain. Furthermore, a method for identifying the M1UK strain is designed according to the primer probe combination, the M1UK strain and other group A streptococcus can be effectively distinguished, and besides the advantages of being high in specificity and accurate in detection result, the method is easy, convenient and rapid to operate and high in detection efficiency, labor cost and time cost are reduced, and the method is suitable for popularization and application. The method can realize rapid and effective non-sequencing-dependent variant strain detection, and has important significance in disease prevention and control and improvement of disease treatment efficiency.

The invention belongs to the technical field of streptococcus bovis identification. The invention provides an identification primer of a streptococcus bovis strain. A primer pair sequence is designed according to a conservative interval of a deoD gene and an rfbD gene. The sequences of the primer pair are as follows: deoD-F1 and rfbD-R1; the sequence information of the deoD-F1 is 5 '-TTCACAGAACTTACAAGGTCACCG-3', and the sequence information of the rfbD-R1 is 5 '-ATTTTTCACAACTGCTTTCTCACAA-3'. By adopting the primer pair disclosed by the invention, a polysaccharide synthesis gene cluster can be obtained and is used for identifying a streptococcus bovis strain, a specific probe can also be used for identifying the streptococcus bovis strain, and compared with a method for analyzing and identifying the strain by using whole genome sequencing, the method is simpler, quicker, low in cost and easy to popularize.

This disclosure relates to immunogenic compositions comprising attenuated and / or dead streptococcal bacterial strains, including modifications that reduce, decrease, or prevent the functional expression of LytC (or its homologues). Such compositions may be used in vaccine compositions. Immunogenic compositions and / or vaccine compositions may be used in methods for inducing an immune response to at least one target streptococcal species and / or its serotype, and / or for preventing or mitigating infections and / or diseases or conditions in a subject caused by at least one target streptococcal species and / or its serotype.

Disclosed are a novel Streptococcus salivarius (S. salivarius G7, KCCM13161P) strain, a composition containing the same for prevention or alleviation of an oral disease, and oral probiotics, and specifically, the novel Streptococcus salivarius (S. salivarius G7, KCCM13161P) strain can prevent, treat, and alleviate periodontal diseases through strong antibacterial and antiinflammatory activities against periodontal disease-causing strains, prevents, treat, and alleviates dental caries through strong antibacterial activity against dental caries-causing strains and biofilm formation inhibitory ability, and suppress halitosis caused by oral diseases, thereby contributing to oral health improvement.

The present invention relates to a Streptococcus zooepidemicus SMT013 strain having increased hyaluronic acid production capacity, a variant thereof, and a method for producing hyaluronic acid using the same. According to one aspect, the Streptococcus zooepidemicus SMT013 strain has increased hyaluronic acid production capacity and can be used to produce hyaluronic acid.

The present invention relates to a composition for producing a fermented dairy product comprising (i) at least one Streptococcus thermophilus (St) strain wherein the St strain is galactose-fermenting wherein the strain carries a mutation in the DNA sequence of the glcK gene encoding the glucokinase protein, wherein the mutation deactivates the glucokinase protein or has a negative effect on the expression of the gene, and (ii) at least one Lactobacillus delbrueckii subsp. Bulgaricus (Lb) strain wherein the Lb strain is lactose deficient and is capable of metabolizing non-lactose carbohydrates.

The present application relates to the animal medical technology field, especially to the Streptococcus suis strain and the vaccine thereof for prevention and treatment, and provides Streptococcus suis type 2, type 3 and type 9 strains screened and obtained, and a trivalent inactivated vaccine prepared by mixing the three strains, which can safely and effectively prevent and protect against the attack of the three pathogenic bacteria of Streptococcus suis.

The present invention relates to Streptococcus thermophilus strains in which the cell envelope proteinase (PrtS) or a homologue thereof is functionally inactive or absent; the use of these PrtS-negative strains for the fermentation of preparations derived from plants, in particular the use of plant-based fermented food or feed products; and methods for the preparation of plant-based fermented products.

The present invention discloses use of Streptococcus thermophilus ST7 for modulating immunity, comprising using the Streptococcus thermophilus ST7 as an active ingredient for modulating immunity, wherein the Streptococcus thermophilus ST7 are deposited under the accession Nos. BCRC911126 and DSM34255. By administering an effective dose of Streptococcus thermophilus ST7 to an individual, the expression level of IL-12p40 on cells can be increased, the gut microbiota can be modulated and the Firmicutes / Bacteroidetes ratio in the intestine increases to improve immunity and antiviral ability.

The application is directed to a method to manufacture pasta-filata cheese based on cultures comprising or consisting of either 1) at least a galactose-positive Streptococcus thermophilus strain as defined herein or 2) at least a Streptococcus thermophilus strain and a Lactococcus lactis strain, and to a stretched curd or cheese produced by this method. The application is also directed to a culture or kit-of-part comprising or consisting of a) a galactose-positive Streptococcus thermophilus strain as defined herein, and b) Lactococcus strain(s) and / or Lactobacillus helveticus strain(s).

The present disclosure is in the field of fermented food technology. It relates to new phage-resistant strains of the species Streptococcus thermophilus, compositions and fermented products comprising the strains, and methods for producing said fermented products.

The dairy industry today faces a problem of providing an alternative to adding sweeteners to fermented milk products in order to achieve the desired sweet taste without the added calories. Furthermore, it would be highly advantageous to establish a method for reducing lactose in fermented milk products to a level which is acceptable for lactose-intolerant consumers. The above problems have been solved by providing mutant Streptococcus thermophilus strains and mutant Lactobacillus delbrueckii subsp. bulgaricus strains that excrete glucose to the milk when the milk is inoculated and fermented with such Streptococcus thermophilus strains and Lactobacillus delbrueckii subsp. bulgaricus strains.Thus, the present invention relates to strains of Streptococcus thermophilus and Lactobacillus delbrueckii subsp. bulgaricus which secrete glucose to the milk substrate during fermentation, as well as to mixed cultures comprising the Streptococcus thermophilus strains and the Lactobacillus delbrueckii subsp. bulgaricus strains, starter cultures comprising the strains and dairy products manufactured with the cultures. The present method also relates to use of the strains for decreasing the lactose content of a fermented food product and for boosting growth of the probiotic BB-12®.

The present invention relates to improved strains of Streptococcus thermophilus as well as methods for generating such strains of Streptococcus thermophilus exhibiting modified rheological properties in fermented milk.

The present invention provides a Streptococcus salivarius strain with a preservation number of CGMCC NO. 13308. The present invention also provides the application of Streptococcus salivarius CGMCC NO. 13308 in the preparation of mutans streptococci growth inhibitors and mutans streptococci biofilm formation inhibitors. The present invention discloses for the first time a new Streptococcus salivarius CGMCC NO. 13308. The cells of Streptococcus salivarius CGMCC NO. 13308 have the function of inhibiting the growth of mutans streptococci, and its M17 fermentation supernatant can significantly reduce the formation amount of mutans streptococci biofilm. The present invention broadens the application prospects of Streptococcus salivarius in the prevention and treatment of dental caries and the industrializable resources.

The present invention supports skin flora by providing an absorbent article having a topsheet coated with a coating composition comprising a prebiotic mixture of fructooligosaccharides (FOS) and inulin, and anionic surfactant. Prebiotic efficacy of the absorbent article having a coating composition comprising a prebiotic mixture of fructooligosaccharides (FOS) and inulin, and anionic surfactant is examined on the strains of Streptococcus salivarius, beneficial microorganism and Staphylococcus aureus, infectious microorganism. Consequently, increase in growth rate of strains of Streptococcus salivarius, beneficial microorganism while decrease in growth rate of Staphylococcus aureus, infectious microorganism is observed.